Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"Erlotinib"”.
-
TRATTAMENTO DEL NSCLC EGFR-MUTATO LOCALMENTE AVANZATO MEDIANTE ASSOCIAZIONE DI ERLOTINIB E RADIOTERAPIA
… dell EGFR, tassi di risposta alla terapia con erlotinib superiori a quelli ottenuti con la chemioterapia. A tale scopo, abbiamo avviato un Progetto di Ricerca per questa categoria di pazienti che prevede l associazione di erlotinib e di radioterapia 3D- conformazionale toracica. Materiali e …
-
Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to NonSmall Cell Lung Cancer
… of this work was to design, develop and evaluate erlotinib-loaded coreshell type lipid albumin hybrid nanoparticles (CSLAHNPs) for targeted drug delivery to nonsmall cell lung cancer (NSCLC). Erlotinib (ETB) is a highly selective, potent and reversible inhibitor of epidermal growth factor receptor …
-
CNS Penetration of Tyrosine Kinase Inhibitors in Mouse Models
… of epidermal growth factor receptor (EGFR), erlotinib (TarcevaTM), and the specific inhibitor of platelet-derived growth factor receptor (PDGFR), crenolanib, as examples of tyrosine kinase inhibitors currently tested for treatment of malignant glioma. Given the poor microdialysis probe …
-
Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines
… tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib and lapatinib, to circumvent resistance to docetaxel, and other chemotherapeutic agents, arising from P-gp over-expression. A HPLC – based method was initially employed to quantify docetaxel levels in cells. The very high taxane levels …
-
The Emergence of Diverse Drug-Resistance Mechanisms from Drug Tolerant Cancer Persister Cells
… is unknown. Here, we compared persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We found, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies had acquired diverse resistance …
-
Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos.
… exposición de los fármacos TKIs administrados (erlotinib, imatinib, lapatinib, pazopanib, sorafenib y sunitinib) y las consecuentes modificaciones de dosis realizadas. Material y método: estudio analítico retrospectivo en el que se han incluido 74 pacientes en tratamiento con TKIs, a los que se …
-
Targeting the Notch-1/IGF-1R/Akt Axis in at Orthotopic Model of Advanced Non-Small Cell Lung Cancer
… Of relevance, the sensitivity of NSCLC cells to erlotinib (EGF-R inhibitor) was increased after MK-0646 treatment. Sequential therapy of MK-0646 followed by erlotinib significantly prolonged survival of the mice compared to each single agent or simultaneous administration of two …
-
Epidermal growth factor and Transforming growth factor α motogenic activities are mediated by Epidermal growth factor receptor : Identification of signalling pathways involved in head and neck cancer
… the Tyrosine kinase inhibitors (Gefitinib and Erlotinib) have been investigated as drugs to target tumours with EGFR mutation. These inhibitors bind to the cytoplasmic domain of the EGFR and compete with ATP and inhibit phosphorylation of the receptor. Another inhibitor of interest is PD98509 …
-
The Investigation of Targets for Therapy in Brain Tumours
… and their responsiveness to three TKIs, erlotinib, gefitinib and imatinib, and two chemotherapy drugs, docetaxel and temozolomide. All data of 26 high-grade gliomas (20 primary glioblastomas, 2 secondary glioblastomas, and 4 grade III astrocytomas including medical history of the patients …
-
Design, Synthesis and Biological Screening of Novel Cucsinspired Estrone Analogues Towards Treatment of Hepatocellular Carcinoma
… IC50 3μM and 2μM, respectively in comparison to Erlotinib IC50 (of 25 μM). Western blot experiments proved that compounds <strong>MMA132</strong> has the ability to bind to the EGFR-TK and inhibit its phosphorylation by 90%. Flow-cytometry/cell cycle arrest study showed that our lead compound …
-
Characterization of mTOR Inhibition and Autophagy Inhibition in Non-Small Cell Lung Cancer
… paclitaxel/carboplatin or the targeted agent erlotinib. Finally, mTOR inhibition and other drug treatments have been shown to lead to autophagy activation. This process of cellular "self-eating" is thought to protect cancer cells from low nutrient availability and therapy induced stress. We …
-
Spontaneous Raman spectroscopy: Exploring applicability in drug discovery and the medical sciences
… background signal. The model compound is erlotinib, an anti-cancer drug with an alkyne group expressing a peak in the CSR. The developed RS system is calibrated using the current gold standard technique Ultra Performance Liquid Chromatography tandem Mass Spectrometry (UPLC-MS/MS). However, …
-
Developing a co-culture model of ovarian cancer to identify immunotherapies that can overcome TGF-β-induced immunosuppression
… that combined effectively with LY, including erlotinib, pazopanib, anti-PD-L1 antibody, and the PAK1 inhibitor FRAX597, each demonstrating increased T cell-mediated cancer cell killing. Our co-culture model has proven to be an effective preclinical tool for screening immunotherapies, providing …
-
Chemoprevention of Lung Carcinogenesis: Aerosol Administration and Deposition in the Mouse Lung
… Four small molecular inhibitors: gefitinib, erlotinib, lapatinib and wortmannin), and four natural agents: resveratrol, caffeine, anthocyanins, and protocatechuic acid), were considered as examples of single agents. Gefitinib and erlotinib were delivered in an aerosol form to reduce the …
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
… kinases inhibitors of EGFR gefitinib and erlotinib, the monoclonal antibody against EGFR cetuximab, and the multi-target tyrosine kinase inhibitor dasatinib. Significantly higher EGFR expression was detected in TNBC compared to HER-2 positive breast cancer cell lines. EGF treatment …
-
Improved delivery of molecularly targeted agents upon modulation of multidrug resistance efflux proteins at mouse blood brain barrier
… pharmacological effect in the treatment regimen. Erlotinib, canertinib, everolimus and temsirolimus were screened as potential modulators of P-gp and Bcrp1 activity. The fact that these drugs inhibit a different class of receptor population than pazopanib and vandetanib, offer a dual advantage for …
-
Design and development of novel tools for the screening and identification of inhibitors of HER receptor family and NFR2 for ovarian cancer therapy
… alone, or in combination with lapatinib or erlotinib. The use of these drugs in combination with bexarotene resulted in the repression of HER1, HER2, HER3 and HER4 expression, inhibition of NRF2, elevation of ROS, depletion of glutathione and enhanced cytotoxicity in PEO1, OVCAR3, SKOV3 and …
-
Hedgehog signaling: a potential therapeutic target for non-small cell lung cancer
… treated these cells with either cisplatin or erlotinib for different time points. My data showed an increase in NSCLCs sensitivity towards cisplatin and erlotinib, suggesting that Hh inhibitors sensitized drug resistant mesenchymal phenotypic NSCLC tumor cells to standard therapy by reverting …
-
SERS & efficacy assessment of anti-cancer drug-nanoparticle conjugates
… molecule tyrosine kinase inhibitor (SM-TKI) erlotinib (EL) that targets a mutant epidermal growth factor receptor (EGFR), was selected as a proof of concept for optical imaging in cancerous cells. The alkyne bond within EL was detected with the vibrational spectroscopy technique, Raman …
Page 1 of 2